Ultralight | $9,300,000 | (Apr 21, 2026)
Sage Haven | $3,000,000 | (Apr 21, 2026)
CREAO AI | $10,000,000 | (Apr 21, 2026)
Certified by Founder
Lodge
Bolden Therapeutics
start up
United States
- Providence, Rhode Island
- 10/01/2024
- Unknown
- Undisclosed Amount
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
- Industry Biotechnology Research
- Website https://www.boldentherapeutics.com/
- LinkedIn https://www.linkedin.com/company/bolden-therapeutics/about/
ViewsML | $4,900,000 | (Apr 21, 2026)
Antioch | $8,500,000 | (Apr 21, 2026)
Wavelet Medical | $7,000,000 | (Apr 21, 2026)
Rivan Industries | $34,000,000 | (Apr 21, 2026)
urfuture | $2,299,785 | (Apr 21, 2026)
TraqCheck | $8,000,000 | (Apr 21, 2026)
Giggles | $1,000,000 | (Apr 21, 2026)
brainjo GmbH | $2,356,020 | (Apr 21, 2026)
Coral(US) | $12,500,000 | (Apr 21, 2026)